ESC 365 - Reversal matters: comprehensive care with dabigatran and idarucizumab.

Open Access

Reversal matters: comprehensive care with dabigatran and idarucizumab.

Session: Anticoagulation and your atrial fibrillation patients: bringing it all together in clinical practice

Topic: Clinical

Speaker: Professor H. Darius (Berlin, DE)

Sponsored by Boehringer Ingelheim

Event: ESC Congress 2018

Congress Session

About the speaker

Professor Harald Darius

Vivantes Neukoelln Medical Center, Berlin (Germany)

10 presentations

0 follower

4 more presentations in this session

NOACs: key features on safety, continuity, and reversibility.

Speaker: Professor E. Hylek (Boston, US)

Unlocking the data: interpreting real-world evidence to inform treatment decisions.

Speaker: Professor T. Villines (Charlottesville, US)

GLORIA-AF: latest results from this prospective study.

Speaker: Professor G. Lip (Liverpool, GB)

Panel discussion and Q&A - Anticoagulation and your atrial fibrillation patients: bringing it all together in clinical practice.

Speaker: Professor E. Hylek (Boston, US) Professor H. Darius (Berlin, DE)

Access the full session

Anticoagulation and your atrial fibrillation patients: bringing it all together in clinical practice

Speakers: Professor H. Darius, Professor E. Hylek, Professor T. Villines, Professor G. Lip, Professor E. Hylek...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

Related content

Open Access

Welcome and introduction.

21 May 2022

Open Access

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment

4 April 2022

Open Access

Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study

28 August 2021

This platform is supported by